Search
Dexamethasone Treatment Options
A collection of 1455 research studies where Dexamethasone is the interventional treatment. These studies are located in the United States. Dexamethasone is used for conditions such as Multiple Myeloma, Lymphoma and Postoperative Pain.
841 - 852 of 1455
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis
Terminated
This is a study to determine the safety, tolerability and maximum tolerated dose of Venetoclax (ABT-199) and dexamethasone in relapsed or refractory amyloid light chain (AL) amyloidosis patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2020
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: AL Amyloidosis
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Completed
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Drugs used in chemotherapy, such as dexamethasone, ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/07/2020
Locations: Rebecca and John Moores UCSD Cancer Center, La Jolla, California +16 locations
Conditions: Lymphoma
Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache
Withdrawn
The purpose of this study is to evaluate the safety and efficacy of intra-arterial (IA) delivery of Dexamethasone and Ketorolac into the arteries supplying the sphenopalatine ganglion (SPG) - a collection of neurons that plays an important role in headache disorders - in patients with refractory migraine, cluster headache and trigeminal neuralgia. All patients must fail standard treatments prior to enrollment in the trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2020
Locations: Weill Cornell Medicine, New York, New York
Conditions: Chronic Migraine, Cluster Headache, Trigeminal Neuralgia
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder
Completed
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Sometimes when chemotherapy is given, it does not stop the growth of cancer cells. The cancer is said to be resistant to chemotherapy. Giving ascorbic acid may reduce drug resistance and allow the cancer cells to be killed. Thalidomide may stop the growth of cancer cells by blocking blood flow... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/23/2020
Locations: Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio +1 locations
Conditions: Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
Completed
Subjects are asked to take part in a clinical research study that tests Eribulin, a new drug. Eribulin is an investigational (experimental) anti-cancer agent that has not been approved by the Food and Drug Administration (FDA) for use in patients with brain metastases. Eribulin is FDA approved for use in patients with metastatic breast cancer but the effect it may or may not have on brain metastases has not been studied.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/20/2020
Locations: University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio +1 locations
Conditions: Metastatic Breast Cancer, Brain Metastases
Detection of miRNAs in HPA Axis Function in Healthy Subjects
Terminated
The proposed study will test dexamethasone effect on miRNA profile in healthy humans. As our data indicate that miRNA levels change over time, the investigators will study the time course of miRNA response to 1 mg IV dexamethasone within 60 minutes after injection. Dexamethasone is used routinely in human subjects for the treatment of inflammatory conditions and as a diagnostic tool in the evaluation of excess cortisol secretion (Cushing's syndrome). For the latter, 1 mg dexamethasone is given o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2020
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Dexamethasone Effect on miRNA Profile in Healthy Humans
the Analgesic Duration of Dexmedetomidine Compared to Dexamethasone as Adjuncts to Single Shot Interscalene Block
Completed
The purpose of the study is to determine if perineural dexmedetomidine can provide increased prolongation of analgesia when compared to perineural dexamethasone in patients receiving regional block for shoulder surgery. If so, dexmedetomidine may serve as a superior adjunct to peripheral nerve blocks in a rapidly evolving, ambulatory-centered surgical setting.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
07/08/2020
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Opioid Use, Unspecified
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer
Completed
This study is designed to compare the treatment effect of PEGPH20 combined with nab-paclitaxel (NAB) and gemcitabine (GEM) \[PAG\] to NAB and GEM \[AG\] in participants with Stage IV previously untreated pancreatic ductal adenocarcinoma (PDA).
The study will have 2 run-in phases, one for each formulation of PEGPH20 (original and new formulations), and a Phase 2 portion. The 2 run-in phases will evaluate the safety and tolerability of the PAG treatment using the original and new succinic acid PE... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/06/2020
Locations: Alabama Oncology, Birmingham, Alabama +50 locations
Conditions: Metastatic Pancreatic Cancer
Short Term Corticosteroids in SARS-CoV2 Patients
Completed
The investigators reviewed the charts of SARS-CoV-2 patients with pneumonia and moderate to severely elevated CRP and worsening hypoxemia who were treated with early, short-term dexamethasone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/22/2020
Locations: The Miriam Hospital, Providence, Rhode Island
Conditions: Corticosteroids, Covid19, SARS-CoV 2, Steroids, Dexamethasone
Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Terminated
The primary objectives are:
Phase 1b:
* To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of oprozomib given orally, once daily, on 2 different schedules.
* To evaluate safety and tolerability
Phase 2:
* To estimate the overall response rate (ORR).
* To evaluate safety and tolerability
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/22/2020
Locations: USC/Norris Comprehensive Cancer Center, Los Angeles, California +12 locations
Conditions: Multiple Myeloma
Ketoconazole and Dexamethasone in Prostate Cancer
Completed
This is an open label, phase II, single center trial of ketoconazole/dexamethasone to determine if the administration of ketoconazole/dexamethasone, after disease progression with ketoconazole/hydrocortisone slows or reverses disease progression in men with progressive prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/12/2020
Locations: University of California, San Francisco, San Francisco, California
Conditions: Prostate Cancer
Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)
Completed
A retrospective, non-interventional, observational, multi-center, drug utilization study to be conducted in adult participants with visual impairment due to DME treated with Ozurdex implants in Germany and Switzerland from 1 January 2015 to 1 September 2017.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2020
Locations: Clinical Trials Registry Team, Irvine, California
Conditions: Diabetic Macular Edema
841 - 852 of 1455